Last Price$3.16NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22

Today's Change-0.22(6.51%)
Bid (Size)$3.03 (1)
Ask (Size)$3.50 (2)
Day Low / High$3.04 - 3.33
Volume2.8 M

View Biotechnology IndustryPeer Comparison as of 05/18/2022


Vaxart Inc ( NASDAQ )

Price: $3.16
Change: -0.22 (6.51%)
Volume: 2.8 M
4:00PM ET 5/18/2022

Protagonist Therapeutics Inc ( NASDAQ )

Price: $7.85
Change: -0.76 (8.83%)
Volume: 1.7 M
4:00PM ET 5/18/2022

Rapt Therapeutics Inc ( NASDAQ )

Price: $13.43
Change: -1.44 (9.68%)
Volume: 424.7 K
4:00PM ET 5/18/2022

Agenus Inc ( NASDAQ )

Price: $1.53
Change: -0.12 (7.27%)
Volume: 4.4 M
4:00PM ET 5/18/2022

MiMedx Group Inc ( NASDAQ )

Price: $3.64
Change: -0.30 (7.61%)
Volume: 543.0 K
4:00PM ET 5/18/2022

Read more news Recent News

Vaxart Q1 Net Loss Widens as Revenue Declines
4:55AM ET 5/10/2022 MT Newswires

Vaxart (VXRT) reported a Q1 net loss Monday of $0.20 per diluted share, widening from a $0.14 loss a year earlier. Four analysts polled by Capital IQ...

-- Earnings Flash (VXRT) VAXART Posts Q1 Revenue $85,000
5:50PM ET 5/09/2022 MT Newswires


--B. Riley Lowers Vaxart's Price Target to $7 from $9 to Reflect Long Term Higher Cost of Capital Amid Current Macro Conditions, Keeps Neutral Rating
8:36AM ET 3/07/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (VXRT) VAXART Reports Q4 Revenue $74,000
4:22PM ET 2/24/2022 MT Newswires


Company Profile

Business DescriptionVaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA. View company web site for more details
Address170 Harbor Way
South San Francisco, California 94080
Number of Employees34
Recent SEC Filing05/18/2022DEFA14A
President, Chief Executive Officer & DirectorAndrei Floroiu
Chief Financial OfficerFuad Ahmad
Chief Scientific Officer & Senior Vice PresidentSean N. Tucker
Senior Vice President-Technical OperationsRichard Schwartz

Company Highlights

Price Open$3.27
Previous Close$3.16
52 Week Range$2.49 - 10.33
Market Capitalization$399.4 M
Shares Outstanding126.4 M
SectorHealth Technology
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.56
Beta vs. S&P 500N/A
Revenue$4.2 M
Net Profit Margin-7,900.22%
Return on Equity-36.68%

Analyst Ratings as of 05/10/2022

Consensus RecommendationConsensus Icon
Powered by Factset